FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers
The FDA has required updated boxed warnings for secondary T-cell malignancy risks in patients who receive CAR T-cell immunotherapies targeting BCMA or CD19, according to a press release from the regulatory agency.1 The agency previously issued a safety …